Phase 1 first-in-human study of dalutrafusp alfa, an anti–CD73-TGF-βtrap bifunctional antibody, in patients with advanced solid tumors

"Ellis et al describe and justify the…” of: [Ellis M.J et al. Connecting Genomic Alterations to Cancer Biology with Proteomics: The NCI Clinical Proteomic Tumor Analysis Consortium.

A Combinatorial Approach for Targeted, Systemic Delivery using Small Molecules and Reversible Masking to Bypass Non-Specific Uptake In Vivo.